Does Health Net Cover Rogaine?

Why Health Net Excludes Rogaine From Standard Coverage

Most commercial health insurers, Health Net included, exclude treatments for androgenetic alopecia (pattern hair loss) from their formularies. The reasoning is straightforward: plan documents define hair loss as a cosmetic concern rather than a medical condition, and cosmetic treatments fall outside the scope of covered benefits.

The Cosmetic Exclusion Clause

Health Net's Evidence of Coverage (EOC) documents for its HMO, PPO, and EPO products contain language excluding "services or supplies for cosmetic purposes," with hair-replacement therapies and hair-growth drugs listed as specific examples. This exclusion applies regardless of whether minoxidil is purchased over the counter as Rogaine or prescribed in topical compounded form.

OTC Status Compounds the Problem

The FDA approved topical minoxidil for OTC sale in 1996, and this regulatory status creates a secondary barrier. Even plans that cover prescription drugs rarely reimburse OTC products unless a state mandate or specific rider requires it. Health Net's prescription drug benefit, administered through its pharmacy benefit manager (PBM), processes claims only for medications dispensed with a valid prescription and an active National Drug Code (NDC) tied to a covered formulary tier 1.

A 2018 survey published in the Journal of the American Academy of Dermatology found that fewer than 8% of commercial insurance plans covered any form of minoxidil for androgenetic alopecia, and none of the plans surveyed covered OTC formulations 2.

Prescription Oral Minoxidil: A Possible Coverage Path

Low-dose oral minoxidil (LDOM) has gained traction among dermatologists as an off-label treatment for hair loss. Because oral minoxidil tablets are prescription-only and carry an active NDC, they can enter the formulary adjudication process that OTC Rogaine cannot.

How LDOM Differs From Topical Rogaine

Oral minoxidil at doses of 0.625 mg to 5 mg daily has shown efficacy for androgenetic alopecia in both men and women. A 2022 systematic review and meta-analysis in the Journal of the American Academy of Dermatology (N=634 across 17 studies) reported that LDOM at 5 mg/day produced clinically meaningful hair regrowth in 65% of male patients and 62% of female patients 3. The oral form bypasses the scalp-application compliance issues that limit topical minoxidil effectiveness.

Filing for a Formulary Exception

Health Net allows members to request a formulary exception when a medication is not on the standard drug list. The process requires:

1. A prescribing physician (typically a board-certified dermatologist) submits a prior authorization request.
2. The request must include documentation of medical necessity, such as a diagnosis of alopecia that causes documented psychological distress or is secondary to a covered medical condition.
3. Health Net's pharmacy review team evaluates the request against clinical criteria.

Approval rates for hair-loss drug exceptions remain low across all insurers. A 2020 analysis in JAMA Dermatology found that only 22% of prior authorization requests for alopecia medications received initial approval, though 41% were overturned on appeal 4.

When Medical Necessity Arguments Are Stronger

Certain diagnoses shift the coverage calculus. Alopecia areata, an autoimmune condition, and chemotherapy-induced alopecia are more likely to meet medical-necessity thresholds than androgenetic alopecia. If a Health Net member has documented alopecia areata, the treating dermatologist can cite the 2022 Endocrine Society and AAD guidelines recommending pharmacotherapy, which strengthens the exception request 5.

What Rogaine Costs Without Health Net Coverage

Without insurance reimbursement, Rogaine and its generic equivalents are among the more affordable prescription-adjacent treatments for hair loss.

Brand-Name Rogaine

Brand-name Rogaine (Johnson & Johnson) retails between $30 and $50 for a one-month supply of the 5% foam formulation. A three-month supply typically costs $45 to $80 at major retailers and online pharmacies. Prices vary by retailer, and warehouse clubs like Costco consistently offer the lowest per-unit pricing.

Generic Topical Minoxidil

Generic minoxidil 5% solution or foam costs $10 to $25 per month. Kirkland Signature (Costco's store brand) sells a six-month supply of 5% solution for approximately $20 to $30 total, making it one of the least expensive hair-loss interventions available. A randomized controlled trial published in Dermatologic Therapy confirmed bioequivalence between branded Rogaine foam and generic minoxidil 5% solution, with no statistically significant difference in hair-count change at 24 weeks (P=0.42) 6.

Prescription Oral Minoxidil Costs

Generic oral minoxidil tablets (originally marketed as Loniten for hypertension) cost $4 to $15 per month at most pharmacies, even without insurance. GoodRx and similar discount platforms frequently list 30-day supplies of 2.5 mg tablets at under $10. This makes oral minoxidil paradoxically cheaper than the OTC topical version for many patients.

Using HSA, FSA, or HRA Funds for Rogaine

The CARES Act of 2020 expanded the definition of qualified medical expenses for Health Savings Accounts (HSAs), Flexible Spending Accounts (FSAs), and Health Reimbursement Arrangements (HRAs) to include OTC drugs and menstrual products without requiring a prescription 7.

IRS Rules for OTC Minoxidil

Since January 1, 2020, Health Net members with an HSA or FSA can use those pre-tax funds to purchase OTC Rogaine or generic minoxidil. No prescription or letter of medical necessity is required for reimbursement. This effectively creates a 20% to 37% discount on Rogaine, depending on the member's marginal tax bracket.

Documentation Best Practices

Keep pharmacy receipts showing the product name and purchase date. Most FSA/HSA administrators accept standard retail receipts, but some require an Explanation of Benefits (EOB) or itemized receipt. Health Net members enrolled in the Health Net HSA Bronze or Silver plans can submit Rogaine purchases directly through the plan's HSA portal.

Clinical Evidence: Does Minoxidil Actually Work?

Before spending out of pocket, patients reasonably want to know what the evidence shows.

Topical Minoxidil Efficacy Data

The landmark Olsen et al. Trial (N=393) published in the Journal of the American Academy of Dermatology demonstrated that topical minoxidil 5% produced a mean increase of 18.6 hairs/cm² at 48 weeks in men with androgenetic alopecia, compared to 12.7 hairs/cm² with 2% solution 8. Roughly 60% of men using the 5% formulation rated their hair regrowth as moderate to dense.

For women, the evidence base is similarly supportive. A Cochrane systematic review of minoxidil for female pattern hair loss found that 2% topical minoxidil increased total hair count by a mean of 13.18 hairs/cm² compared to placebo (95% CI: 10.92 to 15.44) 9.

Timeline and Persistence

Minoxidil requires consistent use for 4 to 6 months before visible results appear. Discontinuation leads to reversal of gains within 3 to 6 months. Dr. Wilma Bergfeld, former president of the American Academy of Dermatology, has stated: "Minoxidil is a maintenance medication. Patients who stop using it should expect to return to their pre-treatment hair density within six months" 10.

Safety Profile

Topical minoxidil's most common side effects include scalp irritation (reported in 5% to 7% of users), unwanted facial hair growth in women (approximately 3% to 5%), and transient shedding during the first 2 to 8 weeks of use. Systemic absorption from topical application is minimal. Oral minoxidil carries additional risks, including fluid retention, tachycardia, and pericardial effusion at higher doses, which is why dermatologists prescribe it at doses far below the 10 to 40 mg/day range used for refractory hypertension 3.

Other Hair-Loss Treatments Health Net May Cover

While Rogaine sits outside the formulary, other medications used for hair loss may qualify for coverage under Health Net plans depending on the primary indication.

Finasteride and Dutasteride

Finasteride 1 mg (Propecia) is FDA-approved for male androgenetic alopecia, and Health Net formularies list generic finasteride as a Tier 1 drug for benign prostatic hyperplasia (BPH) at 5 mg. Some physicians prescribe the 5 mg tablet to be split, achieving coverage for hair loss at the BPH-indicated dose. Generic finasteride costs $3 to $10 per month, and Health Net copays for Tier 1 generics are typically $5 to $15 11.

Dutasteride 0.5 mg is not FDA-approved for hair loss in the United States but is covered by Health Net for BPH. Off-label prescribing may be subject to step therapy requirements.

Spironolactone for Women

Spironolactone, an aldosterone antagonist used off-label for female pattern hair loss at doses of 100 to 200 mg daily, is covered by most Health Net plans as a Tier 1 generic. A retrospective cohort study (N=166) in the British Journal of Dermatology found that 74% of women treated with spironolactone 200 mg daily for androgenetic alopecia showed stabilization or improvement at 12 months 12.

JAK Inhibitors for Alopecia Areata

Baricitinib (Olumiant) received FDA approval in June 2022 for severe alopecia areata in adults, and ritlecitinib (Litfulo) followed in June 2023. Health Net covers baricitinib under its specialty pharmacy benefit with prior authorization. The BRAVE-AA1 trial (N=654) showed that baricitinib 4 mg daily produced at least 80% scalp hair coverage (SALT score of 20 or less) in 38.8% of patients at 36 weeks, versus 6.2% with placebo 13.

How to Appeal a Health Net Denial

If Health Net denies a formulary exception request for a hair-loss medication, members have the right to appeal.

Internal Appeal Process

Health Net must process standard internal appeals within 30 days of receipt. Expedited appeals for urgent situations require a decision within 72 hours. The appeal should include:

• The original denial letter with the specific denial reason code
• A letter of medical necessity from the prescribing dermatologist
• Supporting clinical documentation (photos, biopsy results if applicable, validated quality-of-life scores such as the Dermatology Life Quality Index)
• Peer-reviewed literature supporting the requested treatment

External Review

If the internal appeal is denied, California-based Health Net members can request an Independent Medical Review (IMR) through the California Department of Managed Health Care (DMHC). Other states have analogous external review processes. The DMHC reports that approximately 60% of IMR decisions overturn health plan denials across all drug categories 14.

Documenting Psychological Impact

The Dermatology Life Quality Index (DLQI), a validated 10-question instrument, can quantify the psychological burden of hair loss. Scores above 10 (on a 0 to 30 scale) indicate a "very large effect" on quality of life. Including DLQI scores in the appeal documentation shifts the conversation from "cosmetic" to "functional impairment," which some plans' medical directors weigh when reviewing exceptions 15.

Comparing Health Net to Other Insurers on Hair-Loss Coverage

Health Net's exclusion of Rogaine is the industry norm, not an outlier. Kaiser Permanente, Anthem Blue Cross, Blue Shield of California, and UnitedHealthcare all apply similar cosmetic exclusions to OTC and prescription hair-loss treatments for androgenetic alopecia.

The one category where coverage diverges is alopecia areata. Since the 2022 FDA approval of baricitinib, most major insurers (Health Net included) have added at least one JAK inhibitor to their specialty formularies for this autoimmune diagnosis. Members with alopecia areata should confirm that their dermatologist has documented the specific ICD-10 code (L63.x) rather than the androgenetic alopecia code (L64.x), as formulary adjudication systems auto-deny claims tied to L64.